Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/4/2006 First Published: 8/24/2004


1.		Phase III Randomized Evaluation Of Convection Enhanced Delivery Of IL13-PE38QQR (Interleukin-13 PE38QQR Immunotoxin) Compared To Gliadel® Wafer (Polifeprosan 20 With Carmustine Implant) In Glioblastoma Multiforme Patients At First Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				NEOPHARM-IL13PEI-301 UCLA-040305101, NEOPHARM-IL13PEI-301-R01, PRECISE, NCT00076986

Last Modified: 5/6/2003 First Published: 9/1/1998


2.		Phase II Study of Gliadel Wafers in Adults with Recurrent Supratentorial Low Grade Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				DUMC-1706-02-9R5 DUMC-1706-01-9R4, DUMC-000693-00-4, DUMC-1509-97-10, DUMC-1568-98-10R1, DUMC-1706-00-9R3, DUMC-97131, NCI-G98-1470, NCT00003467

Last Modified: 11/15/2004 First Published: 6/1/1999


3.		Phase II Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Patients With Supratentorial Brain Metastases Undergoing Surgical Resection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NABTT-9802 JHOC-NABTT-9802, NCT00003878, NABTT-9802

Last Modified: 6/20/2008 First Published: 8/6/2006


4.		Phase II Study of Polifeprosan 20 With Carmustine Implant (Gliadel Wafer®) and O6-Benzylguanine in Patients With Recurrent Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				DUMC-5515-06-1R2 DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, NCT00362921

Last Modified: 9/1/2002 First Published: 9/1/1998


5.		Phase I Study of Gliadel Wafers (Carmustine) Plus Irinotecan in Patients with Recurrent Supratentorial High Grade Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				DUMC-0901-02-5R4 DUMC-0901-02-5R2, DUMC-000901-00-5R2, DUMC-000901-01-5R3, DUMC-0797-99-5RI, DUMC-796-98-5, DUMC-98065, UCLA-9812060, NCI-G98-1464, DUMC-0901-01-5R3, NCT00003463

Last Modified: 11/1/1999 First Published: 2/1/1999


6.		Phase I Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Children and Adolescents with Recurrent Supratentorial Glial Tumors (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				Under 18				Pharmaceutical / Industry				RP-RPR132596-150MA NCI-V98-1465

Last Modified: 5/1/2001 First Published: 7/1/1999


7.		Phase I Study of Concurrent Permanent Iodine I 125 Interstitial Seed Implants and Polifeprosan 20 With Carmustine Implant (Gliadel Wafers) in Patients With Recurrent or Refractory Malignant Glioma (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Other				UCMC-98724 UCMC-55853, NCI-V99-1543, NCT00003876

Last Modified: 3/1/2000 First Published: 11/1/1999


8.		Phase I Study of Polifeprosan 20 with Carmustine Implants (Gliadel Wafers) plus Temozolomide in Patients with Recurrent Supratentorial High Grade Glioma (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				UCLA-IRB-9812061 NCI-G99-1600

Last Modified: 2/5/2007 First Published: 3/1/2000


9.		Phase I Study of Polifeprosan 20 With Carmustine Implants (Gliadel Wafers) and O6-Benzylguanine in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NABTT-9803 JHOC-NABTT-9803, NCT00004892, NABTT-9803

Last Modified: 7/30/2004 First Published: 9/1/2002


10.		Phase I Study of Polifeprosan 20 With Carmustine Implant (Gliadel) and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				3 to 21				NCI				PBTC-009 PBTC-009, NCT00045721

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute